Effects of BRAF^V600E mutation on Na⁺/I^- symporter expression in papillary thyroid carcinoma

Abstract

Radioiodine ablation (RIA) therapy is one of the most important treatments for papillary thyroid carcinoma (PTC), but some patients who received ¹³¹I have radioiodine-refractory disease caused by the decreased expreβsion of the Na⁺/I^- symporter (NIS). BRAF^V600E mutation is one poβsible risk factor that can disturb the NIS expression, but the roles are unclear in clinical practice. This research discussed the association of BRAF^V600E mutation and NIS expression in PTC tissue and the clinical implications in RIA therapy. 134 PTC samples were collected between June 2013 and June 2014 from Tongji Hospital affiliated to Tongji Medical College, and their clinical characteristics were analyzed. RT-PCR was used to detect the BRAF^V600E mutation from formalin-fixed paraffin-embedded samples, and immunohistochemistry was applied to detect the NIS expression. IPP software was used to calculate the relative expression quantity of NIS. We found that there was no significant correlation between the absorbance (A) values of NIS and clinicopathologic features in these cases, even thyroid stimulating hormone. BRAF^V600E mutation showed inhibitory effect on the NIS expression without statistically significant difference in all PTC cases (β=–0.0195, P=0.085), but in the subgroup without hashimoto’s thyroiditis (HT), BRAF^V600E mutation could significantly inhibit the NIS expression (β=–0.0257, P=0.046). The results indicate that BRAF^V600E mutation is correlated with a lower expression of NIS in PTCs without HT, suggesting the radioiodine-refractory effects during RIA therapy in these patients.

Keywords

papillary thyroid carcinoma / Na⁺/I^- symporter / BRAF^V600E mutation / radioiodine therapy

References

[1] YooDC, NotoRB, MazzagliaPJ. Controversy over radioiodine ablation in thyroid cancer: who benefits. Surg Clin North Am, 2014, 94(3): 573-586 PMID: 24857577

[2] SpitzwegC, BibleKC, HofbauerLC, et al. . Advanced radioiodine-refractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targets. Lancet Diabetes Endo, 2014, 2(10): 830-842

[3] XingM, HaugenBR, SchlumbergerM. Progress in molecular-based management of differentiated thyroid cancer. Lancet, 2013, 381(9871): 1058-1069 PMCID: 3931461 PMID: 23668556

[4] SeidlinSM, MarinelliLD, OshryE. Radioactive iodine therapy: effect on functioning metastases of adenocarcinoma of the thyroid. J Am Med Assoc, 1946, 132(14): 838-847 PMID: 20274882

[5] ReinersC, HanscheidH, LusterM, et al. . Radioiodine for remnant ablation and therapy of metastatic disease. Nat Rev Endocr, 2011, 7(10): 589-595

[6] KimS, WeiJP, BravemanJM, et al. . Predicting outcome and directing therapy for papillary thyroid carcinoma. Arch Surg, 2004, 139(4): 390-394 PMID: 15078706

[7] SawkaAM, BrierleyJD, TsangRW, et al. . An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer. Endocrinol Metab Clin North Am, 2008, 37(2): 457-480 PMID: 18502337

[8] SacksW, FungCH, ChangJT, et al. . The effectiveness of radioactive iodine for treatment of low-risk thyroid cancer: a systematic analysis of the peer-reviewed literature from 1966 to April 2008. Thyroid, 2010, 20(11): 1235-1245 PMID: 21062195

[9] DuranteC, HaddyN, BaudinE, et al. . Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocr Metab, 2006, 91(8): 2892-2899 PMID: 16684830

[10] PortulanoC, Paroder-BelenitskyM, CarrascoN. The Na+/I-symporter (NIS): Mechanism and medical impact. Endocr Rev, 2014, 35(1): 106-149 PMCID: 3895864 PMID: 24311738

[11] LakshmananA, ScarberryD, ShenDH, et al. . Modulation of sodium iodide symporter in thyroid cancer. HormCancer, 2014, 5(6): 363-373

[12] De VitaG, ZanniniM, CiraficiAM, et al. . Expression of the RET/PTC1 oncogene impairs the activity of TTF-1 and Pax-8 thyroid transcription factors. Cell Growth Differ, 1998, 9(1): 97-103 PMID: 9438393

[13] PortellaG, VitaglianoD, BorselliC, et al. . Human N-ras, TRK-T1, and RET/PTC3 oncogenes, driven by a thyroglobulin promoter, differently affect the expression of differentiation markers and the proliferation of thyroid epithelial cells. Oncol Res, 1999, 11(9): 421-427 PMID: 10821536

[14] DuranteC, PuxedduE, FerrettiE, et al. . BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab, 2007, 92(7): 2840-2843 PMID: 17488796

[15] Riesco-EizaguirreG, Gutierrez-MartinezP, Garcia-CabezasMA, et al. . The oncogene BRAF^V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I-targeting to the membrane. Endocr Relat Cancer, 2006, 13(1): 257-269 PMID: 16601293

[16] WangS, LiangJ, LinY, et al. . Differential expression of the Na+/I-symporter protein in thyroid cancer and adjacent normal and nodular goiter tissues. Oncol Lett, 2013, 5(1): 368-372 PMCID: 3525340 PMID: 23255951

[17] KleimanDA, BuitragoD, CrowleyMJ, et al. . Thyroid stimulating hormone increases iodine uptake by thyroid cancer cells during BRAF silencing. J Surg Res, 2013, 182(1): 85-93 PMCID: 3652238 PMID: 22998776

[18] WangL, GangF, LiuS. The correlation study of sodium/ iodide symporter in autoimmune thyroid diseases. China Foreign Med Treat, 2014, 35: 43-44

[19] Riesco-EizaguirreG, RodriguezI D l, ViejaA, et al. . The BRAF^V600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer. Cancer Res, 2009, 69(21): 8317-8325 PMID: 19861538

[20] ManolovaI, GerenovaJ, IvanovaM. Serum levels of transforming growth factor-beta1 (TGF-beta1) in patients with systemic lupus erythematosus and Hashimoto's thyroiditis. Eur Cytokine Netw, 2013, 24(1): 69-74 PMID: 23614931